ScholarIQanswers from OpenAlex & ORCID
Giorgio V. Scagliotti
ResearcherPublications, citations & collaboration network
Giorgio V. Scagliotti is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Giorgio V. Scagliotti have?
ScholarIQindexed works
Giorgio V. Scagliotti has 1,044 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Giorgio V. Scagliotti have?
ScholarIQcitation count
Giorgio V. Scagliotti has 51,488 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Giorgio V. Scagliotti?
ScholarIQh-index
Giorgio V. Scagliotti has an h-index of 92 in OpenAlex.
What is the i10-index of Giorgio V. Scagliotti?
ScholarIQi10-index
Giorgio V. Scagliotti has an i10-index of 357 in OpenAlex.
What is the ORCID of Giorgio V. Scagliotti?
ScholarIQorcid
The ORCID for Giorgio V. Scagliotti is on the source record.
What is the OpenAlex record for Giorgio V. Scagliotti?
ScholarIQopenalex
The OpenAlex for Giorgio V. Scagliotti is on the source record.
What are the most-cited papers on Giorgio V. Scagliotti?
ScholarIQmost cited works
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis, Élisabeth Brambilla, Masayuki Noguchi, Andrew G. Nicholson, Kim R. Geisinger, Yasushi Yatabe, David G. Beer, Charles A. Powell, Gregory J. Riely, Paul E. Van Schil, Kavita Garg, John H. M. Austin, Hisao Asamura, Valerie W. Rusch, Fred R. Hirsch, Giorgio V. Scagliotti, Tetsuya Mitsudomi, Rudolf M. Huber, Yuichi Ishikawa, James R. Jett, Montse Sánchez‐Céspedes, Jean‐Paul Sculier, Takashi Takahashi, Masahiro Tsuboi, Johan Vansteenkiste, Ignacio I. Wistuba, Pan‐Chyr Yang, Denise R. Aberle, Christian Brambilla, Douglas B. Flieder, Wilbur A. Franklin, Adi F. Gazdar, Michael K. Gould, P S Hasleton, Douglas W. Henderson, Bruce Johnson, David Johnson, Keith M. Kerr, Keiko Kuriyama, Jin Soo Lee, Vincent A. Miller, Iver Petersen, Victor L. Roggli, Rafael Rosell, Nagahiro Saijo, Erik Thunnissen, Ming‐Sound Tsao, David Yankelewitz
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine, Regina Kwon, Walter J. Curran, Yi‐Long Wu, Luis Paz‐Ares
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Giorgio V. Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne Biesma, Johan Vansteenkiste, Christian Manegold, Piotr Serwatowski, U. Gatzemeier, Raghunadharao Digumarti, Mauro Zukin, Jin S. Lee, Anders Mellemgaard, Keunchil Park, Shehkar Patil, Janusz Rolski, Tuncay Göksel, Filippo de Marinis, Lorinda Simms, Katherine P. Sugarman, David R. Gandara
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
Jean‐Pierre Pignon, Hélène Tribodet, Giorgio V. Scagliotti, Jean-Yves Douillard, Frances A. Shepherd, Richard Stephens, Ariane Dunant, Valter Torri, Rafael Rosell, Lesley Seymour, Stephen Spiro, Estelle Rolland, Roldano Fossati, D. Aubert, Keyue Ding, David Waller, Thierry Le Chevalier
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Andrew G. Nicholson, Ming‐Sound Tsao, Mary Beth Beasley, Alain Borczuk, Élisabeth Brambilla, Wendy A. Cooper, Sanja Đačić, Deepali Jain, Keith M. Kerr, Sylvie Lantuéjoul, Masayuki Noguchi, Mauro Papotti, Natasha Rekhtman, Giorgio V. Scagliotti, Paul Van Schil, Lynette M. Sholl, Yasushi Yatabe, Akihiko Yoshida, William D. Travis